Sanofi/Regeneron’s anti-PD-1 product Libtayo may be late to the NSCLC party but strong data from EMPOWER-Lung 1 suggest it could gain traction in the space, especially in patients with high PD-L1 expression levels.
Sanofi/Regeneron Pharmaceuticals, Inc.’s anti-PD1 product Libtayo (cemiplimab) should find a place in the first-line treatment of locally advanced or metastatic non-small cell lung cancer despite its late entry to the market, the full data from its Phase III EMPOWER-Lung 1 study suggest.
The results, presented during a late-breaker session at the European Society for Medical Oncology meeting on 21 September, show the...
The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.
Paying €90m upfront for rights to generalized pustular psoriasis drug.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.
